32 results on '"Cavalier E"'
Search Results
2. A global perspective on the status of clinical metabolomics
- Author
-
Fux, E., primary, Bendt, A.K., additional, Cavalier, E., additional, De Bruyne, S., additional, Friedecky, D., additional, Ivanisevic, J., additional, Lenski, M., additional, and Otvos, J., additional
- Published
- 2024
- Full Text
- View/download PDF
3. Personalized assessment of vitamin D status by a novel metabolic approach
- Author
-
Herrmann, M., primary, Zelzer, S., additional, Cavalier, E., additional, Kleber, M., additional, Drexler-Helmberg, C., additional, Schlenke, P., additional, Curcic, P., additional, Keppel, M., additional, Enko, D., additional, Scharnagl, H., additional, Pilz, S., additional, and März, W., additional
- Published
- 2024
- Full Text
- View/download PDF
4. Artificial intelligence to improve urine crystals recognition
- Author
-
Gadisseur, R., primary, Yilmaz, T., additional, and Cavalier, E., additional
- Published
- 2024
- Full Text
- View/download PDF
5. Asessment of Q-value of serum creatinine in heterogenous population: Preliminary study of Indonesia initiative for renal function evaluation (INA-REN)
- Author
-
Marpaung, F.R., Notobroto, H.B., Tjempakasari, A., Andari, S., Purnami, S.W., Cavalier, E., Aryati, and Santoso, D.
- Published
- 2024
- Full Text
- View/download PDF
6. Assessment of estimated kidney function based on creatinine in indonesian adult populations: Calling for validation of performance
- Author
-
Marpaung, F.R., Notobroto, H.B., Tjempakasari, A., Andari, S., Purnami, S.W., Cavalier, E., Santoso, D., and Aryati
- Published
- 2024
- Full Text
- View/download PDF
7. Performance evaluation of the IgE allergy explorer chip
- Author
-
Gadisseur, R., Israilov, M., Dezfoulian, B., and Cavalier, E.
- Published
- 2024
- Full Text
- View/download PDF
8. Strategic collaboration to address nitrous oxide challenges: Establishment of an international consortium of experts
- Author
-
Gernez, E., Alpdemir, M., Anseeuw, K., Bjorke Monsen, A., Cavalier, E., Croes, K., El Khoury, J., Lee, G., Hamzic, J., Noyce, A., Stankovic, S., Vermeersch, P., and Grzych, G.
- Published
- 2024
- Full Text
- View/download PDF
9. Vitamin D: Analytical Advances, Clinical Impact, and Ongoing Debates on Health Perspectives.
- Author
-
Cavalier E, Makris K, Heijboer AC, Herrmann M, and Souberbielle JC
- Subjects
- Humans, Vitamin D Deficiency, Dietary Supplements, Bone and Bones metabolism, Vitamin D blood, Vitamin D therapeutic use
- Abstract
Background: Vitamin D, acknowledged since the 1930s for its role in preventing rickets, gained additional prominence in relation to fragility fracture prevention in the late 1980s. From the early 2000s, connections between vitamin D deficiency and extra-skeletal pathologies emerged, alongside increased awareness of widespread deficits. This prompted crucial debates on optimal serum concentrations, expected to conclude when the outcomes of high-dose supplementation randomized controlled trials were available. Skepticism arose with inconclusive results from these trials., Content: This review begins with an exploration of vitamin D metabolism, followed by a detailed description of the measurement of vitamin D metabolites and the crucial role of standardization. Subsequent sections focus on the association of vitamin D with bone health and explore the extra-skeletal effects. The review concludes with a comprehensive discussion on the definition of vitamin D status and its implications for supplementation., Summary: Despite standardization efforts, assay variations and challenges still exist, especially in specific patient groups. Vitamin D supplementation has a significant impact on bone metabolism and optimal vitamin D status improves the efficacy of antiresorptive drugs such as bisphosphonates. The extra-skeletal effects of vitamin D remain debated, but may include potential benefits in conditions such as respiratory infections and cancer mortality, particularly in deficient individuals. The definition of vitamin D sufficiency is nuanced, especially when variations in population groups and analytical methods are taken into account. Despite ongoing debates and recent mega-trials tempering enthusiasm, vitamin D remains a complex and essential element in human health. Further research is needed to clarify its role in various health outcomes and guide supplementation strategies., (© Association for Diagnostics & Laboratory Medicine 2024. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
10. Iohexol plasma clearance measurement protocol standardization for adults: a consensus paper of the European Kidney Function Consortium.
- Author
-
Ebert N, Schaeffner E, Seegmiller JC, van Londen M, Bökenkamp A, Cavalier E, Delanaye P, Derain-Dubourg L, Eriksen BO, Indridason OS, Palsson R, Shafi T, Christensson A, Bevc S, Carrara F, Courbebaisse M, Dalton RN, van der Giet M, Melsom T, Methven S, Nordin G, Pottel H, Rule AD, Trillini M, and White CA
- Abstract
International consensus supports the development of standardized protocols for measured glomerular filtration rate (mGFR) to facilitate the integration of mGFR testing in both clinical and research settings. To this end, the European Kidney Function Consortium convened an international group of experts with relevant experience in mGFR. The working group performed an extensive literature search to inform the development of recommendations for mGFR determination using 1-compartment plasma clearance models and iohexol as the exogenous filtration marker. Iohexol was selected as it is non-radio labeled, inexpensive, and safe, can be assayed at a central laboratory, and the other commonly used non-radio-labeled tracers have been (inulin) or are soon to be (iothalamate) discontinued. A plasma clearance model was selected over urine clearance as it requires no urine collection. A 1 compartment was preferred to 2 compartments as it requires fewer samples. The recommendations are based on published evidence complemented by expert opinion. The consensus paper covers practical advice for patients and health professionals, preparation, administration, and safety aspects of iohexol, laboratory analysis, blood sample collection and sampling times using both multiple and single-sample protocols, description of the mGFR mathematical calculations, as well as implementation strategies. Supplementary materials include patient and provider information sheets, standard operating procedures, a study protocol template, and support for mGFR calculation., (Copyright © 2024 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
11. Insight into the potential of bone turnover biomarkers: integration in the management of osteoporosis and chronic kidney disease-associated osteoporosis.
- Author
-
Brouwers P, Bouquegneau A, and Cavalier E
- Subjects
- Humans, Chronic Kidney Disease-Mineral and Bone Disorder therapy, Chronic Kidney Disease-Mineral and Bone Disorder etiology, Chronic Kidney Disease-Mineral and Bone Disorder metabolism, Bone and Bones metabolism, Biomarkers, Osteoporosis etiology, Osteoporosis diagnosis, Bone Remodeling, Renal Insufficiency, Chronic metabolism, Renal Insufficiency, Chronic complications, Bone Density
- Abstract
Purpose of Review: Disturbances in mineral and bone metabolism occurring in osteoporosis and chronic kidney disease-associated osteoporosis place patients at high risk of fracture making these conditions a major public health concern. Due to the limited use of bone histomorphometry in clinical practice, the gold standard for assessing bone turnover, extensive efforts have been made to identify bone turnover markers (BTMs) as noninvasive surrogates. Since the identification of certain commonly used markers several decades ago, considerable experience has been acquired regarding their clinical utility in such bone disorders., Recent Findings: Mounting evidence suggested that BTMs represent a simple, low-risk, rapid and convenient way to obtain data on the skeletal health and that they may be useful in guiding therapeutic choices and monitoring the response to treatment., Summary: BTMs could provide clinicians with useful information, independent from, and often complementary to bone mineral density (BMD) measurements. They have proven valuable for monitoring the effectiveness of osteoporosis therapy, as well as promising for discriminating low and high turnover states. Improved performance is observed when BTMs are combined, which may be useful for selecting treatments for chronic kidney disease-bone mineral disorders (CKD-MBD)., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
12. When and How to Evaluate Vitamin D Status? A Viewpoint from the Belgian Bone Club.
- Author
-
Lapauw B, Laurent MR, Rozenberg S, Body JJ, Bruyère O, Gielen E, Goemaere S, Iconaru L, and Cavalier E
- Subjects
- Humans, Belgium, Practice Guidelines as Topic, Nutritional Status, Cost-Benefit Analysis, Mass Screening methods, Vitamin D blood, Vitamin D analogs & derivatives, Vitamin D Deficiency blood, Vitamin D Deficiency diagnosis, Vitamin D Deficiency epidemiology
- Abstract
Low serum vitamin D levels have been associated with a variety of health conditions which has led the medical community but also the general population to evaluate vitamin D status quite liberally. Nevertheless, there remain questions about the efficacy and cost-effectiveness of such a broad and untargeted approach. This review therefore aims to summarize the current evidence and recommendations on when and how to evaluate vitamin D status in human health and disease. For the general population, most guidelines do not recommend universal screening but suggest a targeted approach in populations at risk. Also, some guidelines do not even recommend evaluating vitamin D status when vitamin D substitution is indicated anyway, such as in children or patients receiving anti-osteoporosis drugs. In those guidelines that recommend the screening of vitamin D status, serum 25(OH)D levels are universally proposed as the preferred screening tool. However, little attention is given to analytical considerations and almost no guidelines discuss the timing and frequency of screening. Finally, there is the known variability in diagnostic thresholds for defining vitamin D insufficiency and deficiency. Overall, the existing guidelines on the evaluation of vitamin D status differ broadly in screening strategy and screening implementation, and none of these guidelines discusses alternative screening modes, for instance, the vitamin metabolic ratio. Efforts to harmonize these different guidelines are needed to enhance their efficacy and cost-effectiveness.
- Published
- 2024
- Full Text
- View/download PDF
13. Diagnostic standard: assessing glomerular filtration rate.
- Author
-
Delanaye P, Pottel H, Cavalier E, Flamant M, Stehlé T, and Mariat C
- Subjects
- Humans, Renal Insufficiency, Chronic diagnosis, Renal Insufficiency, Chronic physiopathology, Renal Insufficiency, Chronic blood, Cystatin C blood, Creatinine blood, Kidney Function Tests methods, Kidney Function Tests standards, Biomarkers blood, Glomerular Filtration Rate
- Abstract
Creatinine-based estimated glomerular filtration rate (eGFR) is imprecise at individual level, due to non-GFR-related serum creatinine determinants, including atypical muscle mass. Cystatin C has the advantage of being independent of muscle mass, a feature that led to the development of race- and sex-free equations. Yet, cystatin C-based equations do not perform better than creatinine-based equations for estimating GFR unless both variables are included together. The new race-free Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation had slight opposite biases between Black and non-Black subjects in the USA, but has poorer performance than that the previous version in European populations. The European Kidney Function Consortium (EKFC) equation developed in 2021 can be used in both children and adults, is more accurate in young and old adults, and is applicable to non-white European populations, by rescaling the Q factor, i.e. population median creatinine, in a potentially universal way. A sex- and race-free cystatin C-based EKFC, with the same mathematical design, has also be defined. New developments in the field of GFR estimation would be standardization of cystatin C assays, development of creatinine-based eGFR equations that incorporate muscle mass data, implementation of new endogenous biomarkers and the use of artificial intelligence. Standardization of different GFR measurement methods would also be a future challenge, as well as new technologies for measuring GFR. Future research is also needed into discrepancies between cystatin C and creatinine, which is associated with high risk of adverse events: we need to standardize the definition of discrepancy and understand its determinants., (© The Author(s) 2023. Published by Oxford University Press on behalf of the ERA.)
- Published
- 2024
- Full Text
- View/download PDF
14. The role of functional vitamin D deficiency and low vitamin D reservoirs in relation to cardiovascular health and mortality.
- Author
-
Herrmann M, Keppel MH, Zelzer S, Alonso N, Cavalier E, Kleber M, Enko D, Scharnagl H, Pilz S, and März W
- Abstract
Objectives: The role of vitamin D deficiency in cardiovascular disease (CVD) is controversial. Inherent biological and analytical limitations compromise the specificity of widely used 25-hydroxyvitamin D [25(OH)D] cut-offs. Simultaneous determination of 25(OH)D and 24,25-dihydroxyvitamin D [24,25(OH)
2 D] permits a functional assessment of vitamin D metabolism. The present study compared the associations of functional vitamin D deficiency and low vitamin D reservoirs with CVD mortality and CVD burden., Methods: 25(OH)D, 24,25(OH)2 D, the degree of coronary obstruction on angiography, high-sensitive cardiac troponin T (hs-cTnT), N-terminal brain natriuretic peptide (NT-proBNP), and 10-year CVD mortality were obtained from 2,456 participants of the LURIC (Ludwigshafen Risk and Cardiovascular Health) study., Results: Neither low 25(OH)D concentrations nor functional vitamin D deficiency were associated with the number of atherosclerotic coronary arteries or the degree of coronary obstruction. Over a median follow-up of 9.9 years, 454 participants died (23.6 %) due to CVD. CVD mortality was doubled in individuals with 25(OH)D concentrations below the widely used cut-off for deficiency of <50 nmol/L [20 ng/mL] (21.6 vs. 11.5 %). In individuals with and without functional vitamin D deficiency, CVD mortality was 25.0 and 16.7 %, respectively. NT-proBNP and heart failure prevalence were also higher in vitamin D deficient individuals., Conclusions: Vitamin D deficient individuals have markedly higher CVD mortality, but only marginally higher hs-cTnT concentrations. A higher prevalence of heart failure and higher NT-proBNP concentrations suggest a link between vitamin D deficiency and cardiac function. The traditional and metabolic assessment of vitamin D status showed comparable associations for the different parameters of cardiac health., (© 2024 the author(s), published by De Gruyter, Berlin/Boston.)- Published
- 2024
- Full Text
- View/download PDF
15. Commentary on Understanding Elevated Vitamin D Measurements to Uncover Hypercalcemia Etiology.
- Author
-
Cavalier E and Souberbielle JC
- Subjects
- Humans, Hypercalcemia blood, Hypercalcemia diagnosis, Hypercalcemia etiology, Vitamin D blood
- Published
- 2024
- Full Text
- View/download PDF
16. Diverse protocols for measuring glomerular filtration rate using iohexol clearance.
- Author
-
Mohamed AAA, Bökenkamp A, Cavalier E, Delanaye P, Ebert N, and van Londen M
- Subjects
- Humans, Kidney Function Tests methods, Clinical Protocols, Glomerular Filtration Rate, Iohexol pharmacokinetics, Contrast Media
- Published
- 2024
- Full Text
- View/download PDF
17. Evaluation of analytical and clinical performance of the AFIAS Tn-I plus assay - a new point-of-care.
- Author
-
Pittie G, Lukas P, Massart M, Cavalier E, and Le Goff C
- Subjects
- Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Young Adult, Limit of Detection, Reproducibility of Results, Sensitivity and Specificity, Biomarkers blood, Myocardial Infarction diagnosis, Myocardial Infarction blood, Point-of-Care Systems standards, Troponin I blood
- Abstract
Background: The objective of this evaluation was to determine the analytical and clinical performance of the AFIAS point-of-care (POC) Tn-I Plus assay (Boditech Med Inc)., Design and Methods: Limit of detection (LOD), limit of quantification (LOQ), repeatability, reproducibility, inter- and intra-individual CV were evaluated using the CLSI guidelines. The study was also designed to estimate the 99
th percentile upper reference limit (URL) and to assess the diagnostic sensitivity and specificity., Results: The precision repeatability CVs were 6.7-8.5% and reproducibility was 7.5-7.6%. The LOD and LOQ were consistent with the manufacturer's specified values of 0.010 ng/mL and 0.030 ng/mL, respectively. The 99th percentile URLs for males (aged 18-75 years) and females (aged 17-65 years) in serum were 0.0300 ng/mL (7.8% CV) and 0.0239 ng/mL (9.4% CV) respectively. Overall 99th percentile URL was 0.0296 ng/mL (8.2% CV). For the overall apparently healthy population, the percentage of measurable cardiac troponin I (cTn-I) values below the 99th percentile (i.e. 0.0296 ng/mL) and above the assay's LOD (= 0.010 ng/mL) was 47,68% (391/820 samples). The diagnostic sensitivity and specificity were 100% with 95% CI (97% - 100%) and 95.2% with 95% CI (93.6% - 96.5%), respectively. No significant differences were observed for the diagnosis of acute myocardial infarction (AMI) between AFIAS Tn-I plus and Abbott ARCHITECT High Sensitive Troponin-I., Conclusion: The clinical performance of AFIAS Tn-I Plus assay for AMI is comparable to the established Abbott ALINITY STAT High Sensitive Troponin-I. This assay is suitable for routine use in clinical laboratories.- Published
- 2024
- Full Text
- View/download PDF
18. Confounding factors of the expression of mTBI biomarkers, S100B, GFAP and UCH-L1 in an aging population.
- Author
-
Calluy E, Beaudart C, Alokail MS, Al-Daghri NM, Bruyère O, Reginster JY, Cavalier E, and Ladang A
- Subjects
- Humans, Male, Female, Aged, Aged, 80 and over, Aging, Brain Concussion diagnosis, Brain Concussion blood, Middle Aged, S100 Calcium Binding Protein beta Subunit blood, Glial Fibrillary Acidic Protein blood, Ubiquitin Thiolesterase blood, Biomarkers blood
- Abstract
Objectives: To evaluate some confounding factors that influence the concentrations of S100 calcium binding protein B (S100B), glial fibrillary acidic protein (GFAP), and ubiquitin carboxyl-terminal hydrolase L-1 (UCH-L1) in older individuals. Indeed, recent guidelines have proposed the combined use of S100B and the "GFAP-UCH-L1" mTBI test to rule out mild traumatic brain injuries (mTBI). As older adults are the most at risk of mTBI, it is particularly important to understand the confounding factors of those mTBI rule-out biomarkers in aging population., Methods: The protein S100B and the "GFAP and UCH-L1" mTBI test were measured using Liaison XL (Diasorin) and Alinity I (Abbott), respectively, in 330 and 341 individuals with non-suspected mTBI from the SarcoPhAge cohort., Results: S100B, GFAP and UCH-L1 were all significantly correlated with renal function whereas alcohol consumption, Geriatric Depression Score (GDS), smoking habits and anticoagulant intake were not associated with any of these three biomarkers. Body mass index (BMI) and age were associated with GFAP and UCH-L1 expression while sex and mini-mental state examination (MMSE) were only associated with GFAP. According to the manufacturer's cut-offs for mTBI rule-out, only 5.5 % of participants were positive for S100B whereas 66.9 % were positive for the "GFAP-UCH-L1" mTBI test. All positive "GFAP-UCH-L1" mTBI tests were GFAP+/UCH-L1-. Among individuals with cystatin C>1.55 mg/L, 25 % were positive for S100B while 90 % were positive for the mTBI test., Conclusions: Our data show that confounding factors have different impacts on the positivity rate of the "GFAP-UCH-L1" mTBI test compared to S100B., (© 2024 the author(s), published by De Gruyter, Berlin/Boston.)
- Published
- 2024
- Full Text
- View/download PDF
19. Familial dysalbuminemic hyperthyroxinemia coexisting with a Grave's disease: a Belgian case report.
- Author
-
Wolff F, Fery F, Désir J, Gadisseur R, Cavalier E, and Cotton F
- Subjects
- Humans, Belgium, Female, Male, Adult, Graves Disease blood, Graves Disease complications, Graves Disease diagnosis, Hyperthyroxinemia, Familial Dysalbuminemic diagnosis, Hyperthyroxinemia, Familial Dysalbuminemic blood
- Published
- 2024
- Full Text
- View/download PDF
20. Associations of Changes in Bone Turnover Markers with Change in Bone Mineral Density in Kidney Transplant Patients.
- Author
-
Jørgensen HS, Claes K, Smout D, Naesens M, Kuypers D, D'Haese P, Cavalier E, and Evenepoel P
- Subjects
- Humans, Bone Density, Parathyroid Hormone, Procollagen, Alkaline Phosphatase, Tartrate-Resistant Acid Phosphatase, Bone Remodeling, Biomarkers, Kidney Transplantation adverse effects, Bone Density Conservation Agents, Bone Diseases, Metabolic
- Abstract
Background: Bone loss after kidney transplantation is highly variable. We investigated whether changes in bone turnover markers associate with bone loss during the first post-transplant year., Methods: Bone mineral density (BMD) was measured at 0 and 12 months, with biointact parathyroid hormone, bone-specific alkaline phosphatase (BALP), intact procollagen type I N -terminal propeptide (PINP), and tartrate-resistant acid phosphatase isoform 5b (TRAP5b) measured at 0, 3, and 12 months post-transplant ( N =209). Paired transiliac bone biopsies were available in a subset ( n =49). Between-group differences were evaluated by Student's t test, Wilcoxon signed-rank test, or Pearson's chi-squared test., Results: Changes in BMD varied from -22% to +17%/yr. Compared with patients with no change (±2.5%/yr), patients who gained BMD had higher levels of parathyroid hormone (236 versus 136 pg/ml), BALP (31.7 versus 18.8 μ g/L), and Intact PINP (121.9 versus 70.4 μ g/L) at time of transplantation; a greater decrease in BALP (-40% versus -21%) and Intact PINP (-43% versus -13%) by 3 months; and lower levels of Intact PINP (36.3 versus 60.0 μ g/L) at 12 months post-transplant. Patients who lost BMD had a less marked decrease, or even increase, in Intact PINP (+22% versus -13%) and TRAP5b (-27% versus -43%) at 3 months and higher Intact PINP (83.7 versus 60.0 μ g/L) and TRAP5b (3.89 versus 3.16 U/L) at 12 months compared with patients with no change. If none of the biomarkers decreased by the least significant change at 3 months, an almost two-fold (69% versus 36%) higher occurrence of bone loss was seen at 12 months post-transplant., Conclusions: Bone loss after kidney transplantation was highly variable. Resolution of high bone turnover, as reflected by decreasing bone turnover markers, associated with BMD gain, while increasing bone turnover markers associated with bone loss., (Copyright © 2023 by the American Society of Nephrology.)
- Published
- 2024
- Full Text
- View/download PDF
21. Extending the cystatin C based EKFC-equation to children - validation results from Europe.
- Author
-
Pottel H, Nyman U, Björk J, Berg U, Bökenkamp A, Dubourg LD, Lemoine S, Goffin K, Grubb A, Hansson M, Larsson A, Littmann K, Åsling-Monemi K, Adeli K, Cavalier E, and Delanaye P
- Subjects
- Child, Humans, Young Adult, Creatinine, Europe, Glomerular Filtration Rate, Renal Insufficiency, Chronic, Algorithms, Cystatin C analysis, Kidney chemistry, Kidney physiology
- Abstract
Background: A new cystatin C based European Kidney Function Consortium (EKFC
CysC ) equation was recently developed for adults, using the same mathematical form as the previously published full age spectrum creatinine based EKFC-equation (EKFCCrea ). In the present study the cystatin C based EKFC-equation is extended to children, by defining the appropriate cystatin C rescaling factor QCysC ., Methods: Rescaling factor QCysC for cystatin C was defined as: a) 0.83 mg/L, exactly as it was defined for young adults in the adult equation, and b) a more complex QCysC -age relationship based on 4th degree cystatin C-age polynomials after evaluation of data from Uppsala, Stockholm and Canada and aggregated data from Germany. The EKFCCysC equation was then validated in an independent dataset in European children (n = 2,293) with measured GFR, creatinine, cystatin C, age, height and sex available., Results: The EKFCCysC with the simple QCysC -value of 0.83 had a bias of -7.6 [95%CI -8.4;-6.5] mL/min/1.73 m2 and a P30-value of 85.8% [95%CI 84.4;87.3] equal to the EKFCCysC with the more complex 4th degree QCysC -value. The arithmetic mean of the EKFCCrea and EKFCCysC with the simple QCysC of 0.83 had a bias of -4.0 [95%CI -4.5;-3.1] mL/min/1.73 m2 and P30 of 90.4% [95%CI 89.2;91.6] similar to using the more complex 4th degree QCysC -polynomial., Conclusion: Using exactly the same QCysC of 0.83 mg/L, the adult EKFCCysC can easily be extended to children, with some bias but acceptable P30-values. The arithmetic mean of EKFCCrea and EKFCCysC results in bias closer to zero and P30 slightly over 90%., (© 2023. The Author(s), under exclusive licence to International Pediatric Nephrology Association.)- Published
- 2024
- Full Text
- View/download PDF
22. Association of circulating hsa-miRNAs with sarcopenia: the SarcoPhAge study.
- Author
-
Millet M, Auroux M, Beaudart C, Demonceau C, Ladang A, Cavalier E, Reginster JY, Bruyère O, Chapurlat R, and Rousseau JC
- Subjects
- Male, Humans, Aged, Sarcopenia genetics, MicroRNAs genetics, MicroRNAs metabolism
- Abstract
Objective: To identify a microRNA signature associated to sarcopenia in community-dwelling older adults form the SarcoPhAge cohort., Methods: In a screening phase by next generation sequencing (NGS), we compared the hsa-miRome expression of 18 subjects with sarcopenia (79.6 ± 6.8 years, 9 men) and 19 healthy subjects without sarcopenia (77.1 ± 6 years, 9 men) at baseline. Thereafter, we have selected eight candidate hsa-miRNAs according to the NGS results and after a critical assessment of previous literature. In a validation phase and by real-time qPCR, we then analyzed the expression levels of these 8 hsa-miRNAs at baseline selecting 92 healthy subjects (74.2 ± 10 years) and 92 subjects with sarcopenia (75.3 ± 6.8 years). For both steps, the groups were matched for age and sex., Results: In the validation phase, serum has-miRNA-133a-3p and has-miRNA-200a-3p were significantly decreased in the group with sarcopenia vs controls [RQ: relative quantification; median (interquartile range)]: -0.16 (-1.26/+0.90) vs +0.34 (-0.73/+1.33) (p < 0.01) and -0.26 (-1.07/+0.68) vs +0.27 (-0.55/+1.10) (p < 0.01) respectively. Has-miRNA-744-5p was decreased and has-miRNA-151a-3p was increased in the group with sarcopenia vs controls, but this barely reached significance: +0.16 (-1.34/+0.79) vs +0.44 (-0.31/+1.00) (p = 0.050) and +0.35 (-0.22/+0.90) vs +0.03 (-0.68/+0.75) (p = 0.054)., Conclusion: In subjects with sarcopenia, serum hsa-miRNA-133a-3p and hsa-miRNA-200a-3p expression were downregulated, consistent with their potential targets inhibiting muscle cells proliferation and differentiation., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
23. Matrix gla protein, a potential marker of tissue remodelling and physiological ageing of the gut in crohn's disease.
- Author
-
Vieujean S, Gillard R, Delanaye P, Seidel L, Bequet E, Salée C, Meuwis MA, Massot C, Pierre N, Meunier P, Cavalier E, and Louis E
- Subjects
- Female, Humans, Matrix Gla Protein, Constriction, Pathologic, Aging, Leukocyte L1 Antigen Complex, Crohn Disease
- Abstract
Background: The inactive dephosphorylated and uncarboxylated form of the matrix Gla protein (dp-ucMGP) has been shown to be increased in plasma of inflammatory bowel disease (IBD) patients. Our aim was to assess if the plasmatic level of dp-ucMGP could reflect disease endoscopic activity, presence of strictures and cumulative structural bowel damage in Crohn's disease (CD) patients., Methods: The plasmatic level of dp-ucMGP was measured in a monocentric cohort of prospectively recruited patients. The analysis was done by chemiluminescent immunoassay on blood samples collected the day of a planned ileocolonoscopy. In addition to classical clinical data (gender, age, body mass index (BMI), disease duration, current treatment), endoscopic data (disease location, Crohn's Disease Endoscopic Index of Severity (CDEIS), mucosal healing (MH), presence of 9 CD lesion types) and biological markers (faecal calprotectin and C-reactive protein (CRP)) were collected. The association between dp-ucMGP level and Lémann index was also investigated. Univariate linear regression was used to investigate the relationship between dp-ucMGP level and different parameters collected., Results: A total of 82 ileocolonoscopies and dp-ucMGP assays were performed in 75 CD patients (45 females; 37 ileocolonic, 19 ileal and 19 colonic diseases) between October 2012 and November 2019. A total of 24 patients (29.3%) showed MH. The dp-ucMGP levels were not associated with MH, CDEIS, faecal calprotectin or CRP levels. Plasmatic dp-ucMGP levels increased significantly with age ( p = 0.0032), disease duration ( p = 0.0033), corticosteroids use ( p = 0.019) and tended to increase in patients with intestinal strictures ( p = 0.086) but not with the Lémann index., Conclusion: The significant increase of plasmatic dp-ucMGP levels with age, disease duration and the trend observed in patients with non-ulcerated strictures may suggest that this extracellular matrix protein could be a marker of tissue remodelling and physiological ageing of the gut.
- Published
- 2024
- Full Text
- View/download PDF
24. Exploring Renal Function Assessment: Creatinine, Cystatin C, and Estimated Glomerular Filtration Rate Focused on the European Kidney Function Consortium Equation.
- Author
-
Pottel H, Delanaye P, and Cavalier E
- Subjects
- Humans, Glomerular Filtration Rate, Creatinine, Kidney physiology, Biomarkers, Cystatin C, Renal Insufficiency, Chronic
- Abstract
Serum creatinine and serum cystatin C are the most widely used renal biomarkers for calculating the estimated glomerular filtration rate (eGFR), which is used to estimate the severity of kidney damage. In this review, we present the basic characteristics of these biomarkers, their advantages and disadvantages, some basic history, and current laboratory measurement practices with state-of-the-art methodology. Their clinical utility is described in terms of normal reference intervals, graphically presented with age-dependent reference intervals, and their use in eGFR equations.
- Published
- 2024
- Full Text
- View/download PDF
25. Performance of the European Kidney Function Consortium (EKFC) creatinine-based equation in United States cohorts.
- Author
-
Delanaye P, Rule AD, Schaeffner E, Cavalier E, Shi J, Hoofnagle AN, Nyman U, Björk J, and Pottel H
- Subjects
- Male, Humans, Female, United States, Creatinine, Cross-Sectional Studies, Glomerular Filtration Rate, Kidney, Cystatin C, Renal Insufficiency, Chronic
- Abstract
Estimating glomerular filtration rate (GFR) is important in daily practice to assess kidney function and adapting the best clinical care of patients with and without chronic kidney disease. The new creatinine-based European Kidney Function Consortium (EKFC) equation is used to estimate GFR. This equation was developed and validated mainly in European individuals and based on a rescaled creatinine, with the rescaling factor (Q-value) defined as the median normal value of serum creatinine in a given population. The validation was limited in Non-Black Americans and absent in Black Americans. Here, our cross-sectional analysis included 12,854 participants from nine studies encompassing large numbers of both non-Black and Black Americans with measured GFR by clearance of an exogenous marker (reference method), serum creatinine, age, sex, and self-reported race available. Two strategies were considered with population-specific Q-values in Black and non-Black men and women (EKFC
PS ) or a race-free Q-value (EKFCRF ). In the whole population, only the EKFCPS equation showed no statistical median bias (0.14, 95% confidence interval [-0.07; 0.35] mL/min/1.73m2 ), and the bias for the EKFCRF (0.74, [0.51; 0.94] mL/min/1.73m2 ) was closer to zero than that for the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI2021 ) equation (1.22, [0.99; 1.47]) mL/min/1.73m2 ]. The percentage of estimated GFR within 30% of measured GFR was similar for CKD-EPI2021 (79.2% [78.5%; 79.9%]) and EKFCRF (80.1% [79.4%; 80.7%]), but improved for the EKFCPS equation (81.1% [80.5%; 81.8%]). Thus, our EKFC equations can be used to estimate GFR in the United States incorporating either self-reported race or unknown race at the patient's discretion per hospital registration records., (Copyright © 2023 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
26. Nitrous oxide abuse direct measurement for diagnosis and follow-up: update on kinetics and impact on metabolic pathways.
- Author
-
Lucas A, Noyce AJ, Gernez E, El Khoury JM, Garcon G, Cavalier E, Antherieu S, and Grzych G
- Abstract
Recreational use of nitrous oxide (N
2 O) has become a major health issue worldwide, with a high number of clinical events, especially in neurology and cardiology. It is essential to be able to detect and monitor N2 O abuse to provide effective care and follow-up to these patients. Current recommendations for detecting N2 O in cases of recreational misuse and consumption markers are lacking. We aimed to update current knowledge through a review of the literature on N2 O measurement and kinetics. We reviewed the outcomes of experiments, whether in preclinical models ( in vitro or in vivo ), or in humans, with the aim to identify biomarkers of intoxication as well as biomarkers of clinical severity, for laboratory use. Because N2 O is eliminated 5 min after inhalation, measuring it in exhaled air is of no value. Many studies have found that urine and blood matrices concentrations are connected to ambient concentrations, but there is no similar data for direct exposure. There have been no studies on N2 O measurement in direct consumers. Currently, patients actively abusing N2 O are monitored using effect biomarkers (biomarkers related to the effects of N2 O on metabolism), such as vitamin B12, homocysteine and methylmalonic acid., (© 2024 Walter de Gruyter GmbH, Berlin/Boston.)- Published
- 2024
- Full Text
- View/download PDF
27. In Reply to A Comment about Analytical Performance Specifications for the Combined Measurement Uncertainty Budget in the Implementation of Metrological Traceability of Parathyroid Hormone.
- Author
-
Cavalier E and Farré-Segura J
- Subjects
- Humans, Uncertainty, Reference Standards, Quality Control, Parathyroid Hormone
- Published
- 2024
- Full Text
- View/download PDF
28. Unveiling a new era with liquid chromatography coupled with mass spectrometry to enhance parathyroid hormone measurement in patients with chronic kidney disease.
- Author
-
Cavalier E, Farré-Segura J, Lukas P, Gendebien AS, Peeters S, Massonnet P, Le Goff C, Bouquegneau A, Souberbielle JC, Delatour V, and Delanaye P
- Subjects
- Humans, Chromatography, Liquid methods, Tandem Mass Spectrometry, Parathyroid Hormone, Renal Insufficiency, Chronic diagnosis, Chronic Kidney Disease-Mineral and Bone Disorder
- Abstract
Precise determination of circulating parathyroid hormone (PTH) concentration is crucial to diagnose and manage various disease conditions, including the chronic kidney disease-mineral and bone disorder. However, the lack of standardization in PTH assays is challenging for clinicians, potentially leading to medical errors because the different assays do not provide equivalent results and use different reference ranges. Here, we aimed to evaluate the impact of recalibrating PTH immunoassays by means of a recently developed LC-MS/MS method as the reference. Utilizing a large panel of pooled plasma samples with PTH concentrations determined by the LC-MS/MS method calibrated with the World Health Organization (WHO) 95/646 International Standard, five PTH immunoassays were recalibrated. The robustness of this standardization was evaluated over time using different sets of samples. The recalibration successfully reduced inter-assay variability with harmonization of PTH measurements across different assays. By recalibrating the assays based on the WHO 95/646 International Standard, we demonstrated the feasibility for standardizing PTH measurement results and adopting common reference ranges for PTH assays, facilitating a more consistent interpretation of PTH values. The recalibration process aligns PTH results obtained from various immunoassays with the LC-MS/MS method, providing more consistent and reliable measurements. Thus, establishing true standardization across all PTH assays is crucial to ensure consistent interpretation and clinical decision-making., (Copyright © 2023 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
29. Alkaline Phosphatase and Parathyroid Hormone Levels: International Variation and Associations With Clinical Outcomes in the DOPPS.
- Author
-
Yamamoto S, Jørgensen HS, Zhao J, Karaboyas A, Komaba H, Vervloet M, Mazzaferro S, Cavalier E, Bieber B, Robinson B, Evenepoel P, and Fukagawa M
- Abstract
Introduction: Secondary hyperparathyroidism (SHPT) increases the risk of fractures and cardiovascular (CV) disease in patients on hemodialysis (HD). The relationship between parathyroid hormone (PTH) and outcomes has been inconsistent, possibly due to variable bone responsiveness to PTH. The KDIGO guideline suggests monitoring total alkaline phosphatase (ALP), but the role of ALP versus PTH in the management of mineral and bone disorder (MBD) is not clear., Methods: The analysis included 28,888 patients on HD in 9 countries in Dialysis Outcomes and Practice Patterns Study (DOPPS) phase 3 to 7 (2005-2021). The primary exposures of interest were normalized ALP and PTH, which are raw values divided by facility upper normal limit, measured at study enrollment. Cox models were used to estimate hazard ratios of all-cause or CV mortality and any or hip fracture adjusted for potential confounders. Linear mixed models, adjusted for potential confounders, were employed to investigate the relationship between normalized ALP levels and patient characteristics., Results: Normalized PTH showed a J-shaped association with all-cause or CV mortality, and a weak linear association with fracture. In contrast, normalized ALP showed a strong association with all outcomes. Factors associated with higher ALP levels after controlling for PTH included Black race, longer dialysis vintage, diabetes mellitus, hypocalcemia, hypophosphatemia, elevated C-reactive protein (CRP), and the use of cinacalcet., Conclusion: Total ALP is a more robust exposure of adverse outcomes than PTH in patients on HD. PTH responsiveness is affected by race, primary renal disease, comorbidities, and mineral metabolism and therapy. Our results indicate that it may be useful to evaluate target organ response, rather than PTH alone when considering the consequences of (SHPT)., (© 2024 International Society of Nephrology. Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF
30. Analysis of progesterone and estrone-sulfate in feces of American Bison using liquid chromatography coupled to mass spectrometry: Technical validation and correlation with blood levels.
- Author
-
Dufour P, Frisée V, Rigaux G, Brutinel F, Egyptien S, Bossaert P, Deleersnyder J, Deleuze S, Peeters S, Le Goff C, Ponthier J, and Cavalier E
- Subjects
- Pregnancy, Female, Animals, Progesterone, Chromatography, Liquid veterinary, Mass Spectrometry veterinary, Feces chemistry, Sulfates analysis, Estrone, Bison
- Abstract
American Bison's wild nature limits blood sample availability to study its endocrinology. This report describes progesterone (P4) and estrone-sulfate (E1S) assays in American Bison feces using Liquid Chromatography coupled with Mass Spectrometry (LC-MS). In 2 ranches, samples of feces (n = 73) and serum (n = 93) were collected in pregnant and nonpregnant American Bison. Feces samples (250 mg) were extracted with methanol, purified, and concentrated. Then, feces and serum samples were assayed using LC-MS, according to our previously described technique. Fecal matrix homogeneity was determined by measuring steroids in different areas of the sample and concentration evolutions were evaluated after storage at room temperature. During the validation process, lower limits of quantification were 20 pg/g (E1S) and 4 ng/g (P4) by meeting the following criteria: relative standard deviation <15% and relative bias <15%. By measuring hormones in different spots from the same sample, a moderate variability for E1S (coefficient of variation [CV] up to 21.3%) and a high variability for P4 (CV up to 85.5%) were highlighted. Correlation between concentrations in feces and in serum was higher for E1S (r = 0.77) than for P4 (r = 0.65) and P4 could be assayed in pregnant and nonpregnant animals whereas E1S was only present in pregnant. Feces storage at room temperature induced modification of steroid concentrations. The quantification of E1S and, at a lower level, of P4 in feces is an interesting alternative to serum assay to describe the pregnancy-related evolution of these steroids in American Bisons, with feces ideally stored frozen and mixed before the LC-MS procedures., Competing Interests: Declaration of Competing Interest Authors have no conflict of interest to declare., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
31. Glomerular Filtration Rate Estimation in Adults: Myths and Promises.
- Author
-
Delanaye P, Cavalier E, Stehlé T, and Pottel H
- Subjects
- Humans, Adult, Kidney Function Tests methods, Biomarkers blood, Glomerular Filtration Rate, Creatinine blood
- Abstract
Background: In daily practice, glomerular filtration rate (GFR) is estimated with equations including renal biomarkers. Among these biomarkers, serum creatinine remains the most used. However, there are many limitations with serum creatinine, which we will discuss in the current review. We will also discuss how creatinine-based equations have been developed and what we can expect from them in terms of performance to estimate GFR., Summary: Different creatinine-based equations have been proposed. We will show the advantages of the recent European Kidney Function Consortium equation. This equation can be used in children and adults. This equation can also be used with some flexibility in different populations., Key Messages: GFR is estimated by creatinine-based equations, but the most important for nephrologists is probably to know the limitations of these equations., (© 2024 S. Karger AG, Basel.)
- Published
- 2024
- Full Text
- View/download PDF
32. Development and validation of an LC-MS/MS method for the simultaneous quantitation of angiotensin (1-7), (1-8), (1-9) and (1-10) in human plasma.
- Author
-
Demeuse J, Huyghebaert L, Determe W, Schoumacher M, Grifnée E, Massonnet P, Dubrowski T, Rechchad M, Segura JF, Peeters S, Cavalier E, and Le Goff C
- Subjects
- Humans, Chromatography, Liquid methods, Angiotensin-Converting Enzyme 2, Tandem Mass Spectrometry methods, Angiotensin I, Peptides, Angiotensin II, Liquid Chromatography-Mass Spectrometry, Cardiovascular Diseases, Peptide Fragments
- Abstract
Cardiovascular diseases have cast a significant negative impact on the lives of millions worldwide. Over the years, extensive efforts have been dedicated to enhancing diagnostic and prognostic tools for these diseases. A growing body of evidence indicates that the angiotensin convertase enzyme (ACE) and the angiotensin convertase enzyme 2 (ACE2), and angiotensin peptide levels could hold a pivotal role in assisting clinicians with the management of cardiovascular conditions, notably hypertension and heart failure. However, despite the considerable body of knowledge in this domain, a void remains in the field of analytical methodologies for these molecules. In this study, we present a fully validated LC-MS/MS method for the precise quantitation of plasma angiotensin (1-7), (1-8), (1-9), and (1-10), following the guidelines set by the Clinical and Laboratory Standards Institute (CLSI). Our method not only enables the accurate quantification of angiotensin peptides but also provides a means to assess ACE and ACE2 activity. Remarkably, our method achieved a Lower Limit of Measurement Interval (LLMI) as low as 5 pg/mL. This has enabled the detection of angiotensin (1-7), (1-8), (1-9) and (1-10) and the accurate quantitation of angiotensin (1-7), (1-8) and (1-10) in all analyzed groups, including healthy controls, patients with high blood pressure, and patients with chronic kidney disease. To our knowledge, our method represents the most sensitive approach allowing for simultaneous quantitation of these four angiotensin peptides. A distinct advantage of our method, when compared to immunoassays, is its high sensitivity combined with comprehensive chromatographic separation of all currently known angiotensin peptides. This combination translates to an exceptional level of selectivity, underscoring the value and potential of our methodology in advancing cardiovascular disease research., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.